Pharmaceuticals & Biopharmaceuticals

South San Francisco, Calif. – September 20, 2026 -- Dualitas Therapeutics has secured a research collaboration and license agreement with Roche worth up to $1 billion, including a $36.5 million upfront payment, to develop bispecific antibody therapeutics for immunology and inflammation diseases.

Dualitas will screen over 300,000 bispecific antibody combinations for Roche

Under the agreement, Dualitas will use its proprietary DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 novel bispecific combinations, in what the company describes as one of the largest-scale bispecific discovery efforts undertaken. Roche will take over all subsequent preclinical development, regulatory, manufacturing and commercial activities for candidates that emerge from the collaboration.

Shanghai – September 20, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics under an exclusive global agreement targeting a single antibody-drug conjugate (ADC) candidate.

Deal structure includes upfront payment, milestones and tiered royalties

The agreement grants Ona Therapeutics exclusive global rights to develop an ADC candidate using WuXi XDC's WuXiTecan-2 platform. The total potential deal value comprises an upfront payment plus development, regulatory and sales milestone payments, with WuXi XDC also eligible for tiered royalties on net sales once the resulting product reaches commercialization. WuXi XDC will additionally provide chemistry, manufacturing and controls (CMC) development and manufacturing support through its integrated ADC CRDMO platform.

London – September 20, 2026 -- Clarivate Plc (NYSE: CLVT) named 22 researchers as its Citation Laureates 2026, identifying scientists whose work the company's Institute for Scientific Information (ISI) considers Nobel-class ahead of this year's Nobel Prize announcements. Since the program began in 2002, 89 previously named Citation Laureates have gone on to win Nobel Prizes.

Stockholm – September 20, 2026 -- Swedish Orphan Biovitrum AB (Sobi) has paid Innate Pharma SA USD 75 million as their strategic oncology partnership becomes legally effective, following the expiration of antitrust waiting periods and satisfaction of other closing conditions.

Partnership clears regulatory hurdles first announced September 20, 2026

The deal, initially disclosed on September 20, 2026, grants Sobi exclusive global commercialisation rights to lacutamab pending accelerated approval, with an option to assume full global development rights if Phase 3 results are positive.

Santa Ana, Calif. – September 20, 2026 -- Robinson Pharma, Inc. (RPI) has received the "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026, recognizing sustained operational performance following a $115 million infrastructure expansion.

Robinson Pharma completes $115 million facility expansion across Southern California

The contract manufacturer finalized a $75 million purchase of a 261,000-square-foot facility in Irvine near John Wayne Airport, adding to a prior $40.7 million acquisition in Santa Ana. The combined investments push Robinson Pharma's regional manufacturing footprint beyond one million square feet.

Company secures USP certification after clearing quality audits

Robinson Pharma achieved United States Pharmacopeia (USP) certification following the expansion, adding to its existing FDA, NSF GRMA, UL GMP, SQF, CCOF, and SCCI credentials.

Franklin, Tennessee – September 20, 2026 -- Adora Life Science has appointed Dr. Clinton D. Morgan, MD, as its full-time Chief Medical Officer, effective September 20, 2026, the company announced.

Neurosurgeon exits clinical practice to lead human trials for veterinary-derived drug

Dr. Morgan previously served on Adora's Board of Directors and consulted part-time on the company's human therapeutic strategy. In his new role, he will direct Adora's human clinical development, regulatory strategy, and scientific research network, and will chair a newly assembled Scientific Advisory Board spanning glycobiology, osteoarthritis, and radiation injury experts.

Québec City – September 19, 2026 -- Linearis Labs has secured funding for two projects under the Terry Fox Research Institute's (TFRI) Digital Health Innovation Fund, part of a combined $40.9 million investment spread across 14 pan-Canadian project teams and 55 partners.

TFRI backs 14 projects with $40.9 million to advance AI-driven precision medicine

The funding, distributed through TFRI's Digital Health & Discovery Platform (DHDP), targets AI-driven health data sharing for precision medicine nationwide. TFRI President and Scientific Director Dr. Jim Woodgett said the initiative reflects research and enterprise coming together to drive innovation.

New York – September 19, 2026 -- Medisights, an AI-native platform for life sciences, has completed a study showing purpose-built AI agents can compress months of qualitative physician research into days while tracking the fast-shifting multiple myeloma treatment landscape.

AI moderators sustain 45-to-60-minute physician interviews to map CAR-T referral logic

Medisights' clinical-grade AI conducted adaptive, humanized conversations with specialists, with interviews routinely running 45 to 60 minutes -- longer engagement than traditional researchers typically secure with physicians. The extended dialogue captured prescribing rationale and geographic variation in CAR-T referral pathways for multiple myeloma, a disease marked by rapidly evolving treatment practices.

Jupiter, Florida – September 19, 2026 -- Myosin Therapeutics, Inc. has been selected as one of just 30 companies for the National Cancer Institute's 2026–2027 Investor Initiatives Showcase, a distinction drawn from NCI's full portfolio of funded companies following a competitive review by more than 70 third-party investors and strategic partners.

NCI selects Myosin from a competitive field of oncology innovators

The 2026–2027 cohort spans biopharmaceuticals, medical devices, diagnostics and digital health, covering first-in-class therapeutics, cell and immune therapies, radioligand therapies, antibody-drug conjugates, RNA medicines, precision drug delivery, AI-enabled cancer technologies, liquid biopsy and multi-omics platforms. Myosin enters this group with a mechanics-based approach that targets molecular nanomotors underlying cancer cell growth, invasion and survival.

Exton, Pa. – September 19, 2026 -- Kibow Biotech's redesigned website, KibowBiotech.com, has been named Best Science Website in the 2026 WebAward Competition, run by the Web Marketing Association across seven judging criteria including design, innovation, content and ease of use.

Kibow expands Renadyl distribution into Canada as part of global rollout

The company's flagship product, Renadyl®, a clinically studied probiotic dietary supplement built on gut-kidney axis research, is now sold worldwide, with an upcoming expansion into Canada marking the latest step in Kibow's international access strategy.

Kibow prepares Renaphil launch to extend kidney probiotic science to pets

The company is developing RenaphilTM, a kidney probiotic formulated specifically for cats and dogs, applying nearly 30 years of gut-kidney research to companion-animal health.